MARKET

SLNO

SLNO

SOLENO THERAPEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4201
+0.0001
+0.02%
After Hours: 0.4100 -0.0101 -2.40% 16:19 01/18 EST
OPEN
0.4200
PREV CLOSE
0.4200
HIGH
0.4700
LOW
0.4069
VOLUME
99.62K
TURNOVER
--
52 WEEK HIGH
3.360
52 WEEK LOW
0.4011
MARKET CAP
33.53M
P/E (TTM)
-1.0830
1D
5D
1M
3M
1Y
5Y
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, ...
GlobeNewswire · 01/05 13:00
Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround
Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a ...
Zacks · 11/24/2021 15:00
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq St...
GlobeNewswire · 11/19/2021 21:05
BRIEF-Soleno Therapeutics Q3 Loss Per Share $0.10
reuters.com · 11/11/2021 00:05
BRIEF-Soleno Therapeutics Reports Q3 2021 Financial Results
reuters.com · 11/10/2021 22:36
Soleno Therapeutics Q3 EPS $(0.10) Up From $(0.11) YoY
Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.10) per share. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.
Benzinga · 11/10/2021 22:10
Soleno Therapeutics EPS beats by $0.01
Soleno Therapeutics (NASDAQ:SLNO): Q3 GAAP EPS of -$0.10 beats by $0.01. As of September 30, 2021, Soleno had cash and cash equivalents of approximately $28.2M, as compared to $49.2M as
Seekingalpha · 11/10/2021 21:53
Hedge Funds Are Buying Soleno Therapeutics, Inc. (SLNO)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge f...
Insider Monkey · 10/04/2021 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLNO. Analyze the recent business situations of SOLENO THERAPEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SLNO stock price target is 6.00 with a high estimate of 7.00 and a low estimate of 5.00.
High7.00
Average6.00
Low5.00
Current 0.4201
EPS
Actual
Estimate
-0.11-0.08-0.06-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 57
Institutional Holdings: 29.62M
% Owned: 37.11%
Shares Outstanding: 79.81M
TypeInstitutionsShares
Increased
9
656.36K
New
5
751.04K
Decreased
10
590.48K
Sold Out
13
1.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.74%
Pharmaceuticals & Medical Research
-1.37%
Key Executives
Non-Executive Chairman/Independent Director
Ernest Mario
President/Chief Executive Officer/Chief Operating Officer/Director
Anish Bhatnagar
Chief Financial Officer
James Mackaness
Vice President
Patricia Hirano
Vice President
Kristen Yen
Independent Director
William Harris
Independent Director
Gwen Melincoff
Independent Director
Andrew Sinclair
Independent Director
Birgitte Volck
No Data
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for the treatment of rare diseases. Its lead drug Diazoxide Choline Controlled-Release tablets (DCCR) is a potent ATP-sensitive potassium (KATP) channel activator. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like Prader-Willi syndrome (PWS) to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. It appears that many of the problematic behaviors in conditions like PWS may have hyperphagic drive as a root cause and may therefore be improved by addressing hyperphagia. The Company has a Fast-Track designation for DCCR in PWS and orphan drug designation for the drug in the United States and European Union.

Webull offers kinds of Soleno Therapeutics Inc stock information, including NASDAQ:SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.